NEW YORK, April 6, 2016 /PRNewswire/ -- According to Kalorama Information, the market for tests for cancer using biomarkers grew to $4.8 Billion in 2015. The firm projects that the market will grow to $7.4 Billion in 2020. Cancer is the number two cause of death, behind only cardiovascular disease. The most common types of cancer worldwide include breast cancer, colorectal cancer, lung cancer, and prostate cancer. For these and other types of cancer, novel biomarkers, therapies, and diagnostic tests are being developed. The healthcare market researcher's report, Cancer Markers, provides market assessment, estimate and competitive analysis for tests for oncology that use biomarkers.
Cancer Markers can be found at Kalorama Information: http://www.kaloramainformation.com/redirect.asp?progid=88559&productid=9943935.
"Once a cancer is diagnosed, physicians often need additional information about the genetic changes and characteristics of a cancer to aid in the decision about what therapy to select to treat the patient," said Bruce Carlson, Publisher of Kalorama Information. "These genetic changes may result in over-expression of certain proteins, or in the absence of certain protein activities. A growing number of options and tests are becoming available for this."
One example is the growing number of companion diagnostic tests that are used to determine the presence or absence of a specific biomarker (genetic mutation or expressed protein) that is the target of a targeted therapy. A companion diagnostic is an in vitro diagnostic device or an imaging tool that provides information that is essential for the safe and effective use of a corresponding drug or biological product. These tests can be used to predict whether or not a patient is likely to respond to treatment with that targeted therapy.
Technologies such as PCR (polymerase chain reaction), in situ hybridization and flow cytometry are used to detect the presence of biomarkers. The large and growing cancer biomarker market has attracted a lot of attention, and companies entering the market. Cancer diagnostics is a highly competitive field. Competition is such that new companies – or older companies developing new diagnostic tests based on novel biomarkers – must address the issue of how they stand out from the crowd of the many other companies offering competing tests.
Cancer Markers provides the following data: worldwide cancer biomarkers diagnostic market, 2015 and 2020; selected international agreements; worldwide cancer biomarkers diagnostic market percentage; estimated global incidence and mortality due to cancer, 2012, by regions of the world; selected widely used tumor markers; selected biomarkers and biomarker panels to assess risk of cancer, and companies developing/marketing these biomarkers; selected biomarkers and biomarker panels for cancer screening, and companies developing/marketing these biomarkers; selected biomarkers and biomarker panels for diagnosis and/or monitoring of cancer, and companies developing/marketing these biomarkers; selected biomarkers and biomarker panels to predict prognosis of cancer, and companies developing/marketing these biomarkers; selected biomarkers and biomarker panels to predict response to therapy, and companies developing/marketing these biomarkers; selected FDA cleared/approved companion diagnostic tests, and companies developing/marketing these biomarkers; selected companies developing/marketing cancer tests; common next generation molecular test traits; selected sample preparation reagents; and selected cancer test innovations, 2015.
The report provides market assessment, estimate and competitive analysis for tests for oncology that use biomarkers. This includes a range of technologies made by scores of companies. The report contains products designed to determine risk for cancer, screen for cancer, test for cancer, aid in prognosis and personalize therapy. Among the technologies are the following: histology/cytology, immunohistochemistry, in situ hybridization, immunoassays - tumor markers, flow cytometry, rapid tests, and molecular marker-based mapping.
Cancer Markers provides estimates for these segments for 2015 and 2020. In addition, some specific marker breakouts are provided along with significant detail of products on the market. This report reviews the progression of cancer diagnostic technologies over the past 10-15 years and notes some trends in test strategies as well.
The report contains company profiles, including coverage of the following competitors: Abbott Laboratories, Alere Inc. (Abbott), bioMérieux SA, Hologic, Inc., Illumina, Inc., QIAGEN N.V., Roche, and Thermo Fisher Scientific, Inc.
For more information on Cancer Markers visit: http://www.kaloramainformation.com/redirect.asp?progid=88559&productid=9943935.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kalorama-cancer-biomarker-testing-market-grows-to-48-billion-300247077.html
SOURCE Kalorama Information